Welcome to the
VAD PARADIGM Series.

A unique online platform to access exclusive clinical presentations from world-renowned thought leaders in the field of mechanical circulatory support, regarding the latest findings and research in LVAD technology and clinical results.

VOL I

Advances in LVAD Design

Improving reliability and minimizing risk of stroke and thrombosis

Read Monograph

Steve Reichenbach, PhD
Senior Director, Technology Development
Thoratec Corporation, Pleasanton, CA

Precision engineering coupled with 30 years of clinical experience that is reflected in its design, HeartMate II® has demonstrated the lowest published rates of stroke and pump thrombosis of any continuous flow device. Dr. Reichenbach presents the unique technical attributes of the HeartMate II that have led to its clinical success and established its reputation as a best-in-class device.

 

About the Speaker:

Dr. Reichenbach has more than 2 decades of experience in the cardiothoracic discipline. He served as the HeartMate II program manager, overseeing its development, and is the published author of more than 20 peer-reviewed articles.


VOL II

Are LVADs Ready to be Mainstream?

A review of outcomes, safety & efficacy in advanced heart failure therapy

Read Monograph

Joseph G. Rogers, MD
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

The literature and clinical data support the HeartMate II® as a proven therapy for a broader patient population suffering from advanced stage heart failure. Dr. Joseph Rogers discusses the clinical outcomes of the first and only FDA-approved continuous flow device for both Bridge-to-Transplantation and Destination Therapy—demonstrating improved survival, quality of life, and functional capacity, as well as low rates of major adverse events.

 

About the Speaker:

Dr. Rogers is the medical director of the Cardiac Transplant Program at Duke University Medical Center. As one of the preeminent cardiologists in the country, he helps to evaluate and improve the processes of LVAD patient management. His areas of interest include acute and chronic heart failure, cardiac transplantation, and mechanical circulatory support.


VOL III

Advances in LVAD Patient Management

Clinical strategies to minimize adverse events

Read Monograph

Mark Slaughter, MD
Professor of Surgery, Division of Thoracic
and Cardiovascular Surgery
University of Louisville, Kentucky

Comprehensive guidelines defining optimal clinical strategies were developed by an interdisciplinary group to articulate how to achieve the lowest rate of adverse events in advanced heart failure patients supported by left ventricular assist device (LVAD) therapy. Dr. Mark Slaughter assesses the impact of both refined clinical strategies and LVAD design advancements on improving patient outcomes.

 

About the Speaker:

Dr. Slaughter is an internationally acclaimed expert in heart transplants and ventricular assist devices. His experience includes the utilization of VADs for Destination Therapy, Bridge-to-Transplantation, myocardial recovery, and rescue surgeries. He has published over 50 peer-reviewed articles and contributed chapters to multiple books.


VOL IV

Contemporary Outcomes With the HeartMate II® LVAS

New studies demonstrate increased survival for heart failure patients

David J. Farrar, PhD
Vice President, Research & Scientific Affairs
Thoratec Corporation, Pleasanton, California

New LVAD clinical studies focusing on a broad range of topics, including risk models for patient selection, stratification of outcomes based on INTERMACS profiles, impact of gender on outcomes, and exploration of a novel driveline tunneling technique, offering new insights into improved LVAD patient management. Dr. David Farrar discusses these clinical outcomes and recent studies demonstrating increased survival and decreased adverse events for advanced heart failure patients.

 

About the Speaker:

Dr. Farrar is a recognized leader in the area of cardiovascular research, having worked in the field of mechanical circulatory support for more than 35 years. At Thoratec, he has led the company's efforts in advancing clinical science related to VADs and exploring adjuvant heart failure therapies.